Regional differences in pediatric pneumococcal vaccine schedules for Indigenous children in Canada: an environmental scan.
Immunization programs
Immunization schedule
Indigenous health
Pneumococcal vaccine
Vaccine policy
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
26 Aug 2024
26 Aug 2024
Historique:
received:
26
10
2023
accepted:
05
08
2024
medline:
27
8
2024
pubmed:
27
8
2024
entrez:
26
8
2024
Statut:
epublish
Résumé
Streptococcus pneumoniae bacteria causes substantial morbidity and mortality worldwide, especially in children under 5 years of age. Prevention of these outcomes by pneumococcal conjugate vaccines (PCV) is an important public health initiative, supported by publicly funded vaccination programs in Canada. While the National Advisory Committee on Immunization (NACI) provides national recommendations for vaccination schedules, decisions on vaccination program delivery are made regionally, creating potential for variability across the country. In addition, defining the groups that are most at risk has become a complex endeavor for provinces and territories in Canada, specifically considering Indigenous children. In this environmental scan, we reviewed policy documents, provincial/territorial and international PCV schedules, and scientific literature, and consulted with vaccination program stakeholders and experts from across the country, in order to understand the evolution of PCV vaccination guidelines and policies in Canada and identify whether and how the needs of Indigenous children are addressed. As of March 2023, most regions do not specify particular vaccination requirements for Indigenous children; however, three provinces identify Indigenous children as "high risk" and use varying language to recommend a four dose, rather than the routine three dose, schedule. Our results also draw attention to evidence gaps supporting a differing practice for Indigenous populations. Future PCV program innovation requires inclusive and clear policies as well as definitive evidence-based policies and practices in order to improve equitable population health.
Sections du résumé
BACKGROUND
BACKGROUND
Streptococcus pneumoniae bacteria causes substantial morbidity and mortality worldwide, especially in children under 5 years of age. Prevention of these outcomes by pneumococcal conjugate vaccines (PCV) is an important public health initiative, supported by publicly funded vaccination programs in Canada. While the National Advisory Committee on Immunization (NACI) provides national recommendations for vaccination schedules, decisions on vaccination program delivery are made regionally, creating potential for variability across the country. In addition, defining the groups that are most at risk has become a complex endeavor for provinces and territories in Canada, specifically considering Indigenous children.
METHODS
METHODS
In this environmental scan, we reviewed policy documents, provincial/territorial and international PCV schedules, and scientific literature, and consulted with vaccination program stakeholders and experts from across the country, in order to understand the evolution of PCV vaccination guidelines and policies in Canada and identify whether and how the needs of Indigenous children are addressed.
RESULTS
RESULTS
As of March 2023, most regions do not specify particular vaccination requirements for Indigenous children; however, three provinces identify Indigenous children as "high risk" and use varying language to recommend a four dose, rather than the routine three dose, schedule. Our results also draw attention to evidence gaps supporting a differing practice for Indigenous populations.
CONCLUSIONS
CONCLUSIONS
Future PCV program innovation requires inclusive and clear policies as well as definitive evidence-based policies and practices in order to improve equitable population health.
Identifiants
pubmed: 39187809
doi: 10.1186/s12913-024-11400-6
pii: 10.1186/s12913-024-11400-6
doi:
Substances chimiques
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
990Informations de copyright
© 2024. The Author(s).
Références
Public Health Agency of Canada. Pneumococcal vaccine: Canadian Immunization Guide. 2023. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-16-pneumococcal-vaccine.html . Accessed 3 Aug 2023.
Public Health Agency of Canada. Invasive Pneumococcal Disease for healthcare professionals. 2014. https://www.canada.ca/en/public-health/services/immunization/vaccine-preventable-diseases/invasive-pneumococcal-disease/health-professionals.html . Accessed 3 Aug 2023.
Helferty M, Rotondo JL, Martin I, Desai S. The epidemiology of invasive pneumococcal disease in the Canadian North from 1999 to 2010. Int J Circumpolar Health. 2013;72:21606.
doi: 10.3402/ijch.v72i0.21606
Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kang Y. Vaccination coverage among children aged 19–35 months — United States, 2017. MMWR Morb Mortal Wkly Rep. 2017;66:134–5.
doi: 10.15585/mmwr.mm6643a3
Jackson J, Sonneveld N, Rashid H, Karpish L, Wallace S, Whop L et al. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander People, Australia, 2016–2019. Commun Dis Intell. 2023;47.
Public Health Agency of Canada. Highlights from the 2021 childhood National Immunization Coverage Survey (cNICS). 2023. https://www.canada.ca/en/public-health/services/immunization-vaccines/vaccination-coverage/2021-highlights-childhood-national-immunization-coverage-survey.html . Accessed 3 Aug 2023.
MacDonald SE, Bell CA, Simmonds KA. Coverage and determinants of uptake for privately funded rotavirus vaccine in a Canadian birth cohort, 2008–2013. Pediatr Infect Dis J. 2016;35:e177–9.
doi: 10.1097/INF.0000000000001125
pubmed: 26954603
United Nations. Indigenous Peoples at the United Nations. https://www.un.org/development/desa/indigenouspeoples/about-us.html . Accessed 13 Sep 2023.
Public Health Agency of Canada. Addressing Stigma: Towards a more inclusive health system. 2019. https://www.canada.ca/content/dam/phac-aspc/documents/corporate/publications/chief-public-health-officer-reports-state-public-health-canada/addressing-stigma-what-we-heard/stigma-eng.pdf . Accessed 3 March 2023.
MacDonald SE, Kenzie L, Letendre A, Bill L, Shea-Budgell M, Henderson R, et al. Barriers and supports for uptake of human papillomavirus vaccination in Indigenous people globally: a systematic review. PLOS Glob Public Health. 2023;3:e0001406.
doi: 10.1371/journal.pgph.0001406
pubmed: 36962871
pmcid: 10021254
Aylsworth L, Manca T, Dubé È, Labbé F, Driedger SM, Benzies K, MacDonald N, Graham J, MacDonald SM. A qualitative investigation of facilitators and barriers to accessing COVID-19 vaccines among Racialized and Indigenous Peoples in Canada. Human Vaccines & Immunotherapeutics, 2022; 18(6). https://doi.org/10.1080/21645515.2022.2129827
Public Health Agency of Canada. COVID-19: How provinces and territories make decisions about how, who and when to vaccinate. 2021. https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19/vaccines/provinces-territories-decisions-how-who-when-vaccinate.html . Accessed 3 Aug 2023.
Government of Canada. Non-insured health benefits for First Nations and Inuit. https://sac-isc.gc.ca/eng/1572537161086/1572537234517
Government of Canada Indigenous Services Canada. Indigenous health care in Canada. 2021. https://www.sac-isc.gc.ca/eng/1626810177053/1626810219482 . Accessed 3 Aug 2023.
Queen’s University. Indigenous Terminology Guide. https://www.queensu.ca/indigenous/ways-knowing/terminology-guide . Accessed 6 Sep 2023.
Charlton P, Kean T, Liu RH, Nagel DA, Azar R, Doucet S, et al. Use of environmental scans in health services delivery research: a scoping review. BMJ Open. 2021;11:e050284.
doi: 10.1136/bmjopen-2021-050284
pubmed: 34758992
pmcid: 8587593
Wilburn A, Vanderpool RC, Knight JR. Environmental scanning as a public health tool: Kentucky’s human papillomavirus vaccination project. Prev Chronic Dis. 2016;13.
Tam TWS. National Advisory Committee on Immunization statement on recommended use of pneumoccocal conjugate vaccine. CCDR. 2002;28:ACS–2.
Embree J, Deeks SL, Langley J. National Advisory Committee on Immunization update on the recommendations for the routine use of pneumococcal conjugate vaccine for infants. CCDR. 2006;32:ACS–4.
McGeer A, Desai S. National Advisory Committee on Immunization update on pediatric invasive pneumococcal disease and recommended use of conjugate pneumococcal vaccines. CCDR. 2010;36:ACS–3.
Degani N, Navarro C, Deeks SL, Lovgren M. Invasive bacterial diseases in Northern Canada. Emerg Infect Dis. 2008;14:34–40.
doi: 10.3201/eid1401.061522
pubmed: 18258074
pmcid: 2600163
Desai S, McGeer A, Quach-Thanh C, Elliott D. National Advisory Committee on immunization update on the use of conjugate pneumococcal vaccines in childhood. Can Commun Dis Rep. 2010;36 ACS–12:1–21.
doi: 10.14745/ccdr.v36i00a12
National Advisory Committee on Immunization. Interim guidance on the use of pneumococcal 15-valent conjugate vaccine (PNEU-C-15) in pediatric populations. Ottawa: Public Health Agency of Canada. 2023. https://www.canada.ca/content/dam/hc-sc/documents/services/publications/vaccines-immunization/national-advisory-committee-immunization-interim-guidance-pneumococcal-15-valent-conjugate-vaccine-pneu-c-15-pediatric-populations/national-advisory-committee-immunization-interim-guidance-pneumococcal-15-valent-conjugate-vaccine-pneu-c-15-pediatric-populations.pdf
Government of Alberta. Pneumococcal Vaccine, 13-valent Conjugate: Prevnar 13. 2018. https://open.alberta.ca/dataset/aip/resource/1e0e2935-1d18-455c-ade0-4bb728adcec5/download/AIP-BP-Pneu-C-13.pdf
British Columbia Centre for Disease Control. Communicable Disease Control Manual Chap. 2: Immunization. Vancouver, British Columbia. 2020. http://www.bccdc.ca/resource-gallery/Documents/Guidelines%20and%20Forms/Guidelines%20and%20Manuals/Epid/CD%20Manual/Chapter%202%20-%20Imms/Part_1_Schedules.pdf
Government of Manitoba. Manitoba’s immunization program: vaccines offered free-of-charge. Province of Manitoba - Health. 2022. https://www.gov.mb.ca/health/publichealth/cdc/vaccineeligibility.html . Accessed 3 Aug 2023.
Government of New Brunswick. Immunization Program Guide Standard 3.3: Eligibility criteria for publicly funded vaccines/biologics. 2019. https://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/CDC/HealthProfessionals/NBIPG-standard3-3-e.pdf
Government of Newfoundland and Labrador. Newfoundland and Labrador Immunization Manual: Routine immunization products. 2022. https://www.gov.nl.ca/hcs/files/Section-3-Routine-Immunization-Products-Sept-15.pdf
Nova Scotia Health and Wellness. Publicly funded vaccine/immunoglobulin eligibility policy. 2019. https://www.nccih.ca/docs/determinants/FS-AccessHealthServicesSDOH-2019-EN.pdf
Government of Northwest Territories. Northwest Territories Immunization Schedule: Program guidelines. 2022. https://www.hss.gov.nt.ca/professionals/sites/professionals/files/resources/nwt-immunization-schedule-health-care-professionals.pdf
Government of Nunavut. Nunavut Immunization Manual. 2021. https://www.gov.nu.ca/sites/default/files/immunization_manual_edited_may_2021.pdf
Ontario Health. Publicly Funded Immunization Schedules for Ontario. 2022. https://www.health.gov.on.ca/en/pro/programs/immunization/docs/Publicly_Funded_ImmunizationSchedule.pdf
Government of Prince Edward Island Department of Health and Wellness. Childhood Immunizations. 2018. https://www.princeedwardisland.ca/en/information/health-and-wellness/childhood-immunizations . Accessed 3 Aug 2023.
Government of Québec. Pneumococcal vaccination program. Gouvernement du Québec. 2020. https://www.quebec.ca/en/health/advice-and-prevention/vaccination/pneumococcal-vaccination-program . Accessed 3 Aug 2023.
Government of Saskatchewan. Saskatchewan Immunization Manual, Chap. 10: Biological Products. 2022. https://www.ehealthsask.ca/services/manuals/Documents/sim-chapter10.pdf
Yukon Department of Health and Social Services. Yukon Immunization Program Manual, HPV Vaccine. 2021. https://yukon.ca/sites/yukon.ca/files/hss/hss-section-8-pneumococcal-vaccines.pdf
First Nations Health Authority. Tripartite Framework Agreement. https://www.fnha.ca:443/about/governance-and-accountability/tripartite-framework-agreement . Accessed 3 Aug 2023.
Kobayashi M, Farrar JL, Gierke R, Leidner AJ, Campos-Outcalt D, Morgan RL, et al. Use of 15-Valent pneumococcal conjugate vaccine among U.S. children: updated recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1174–81.
doi: 10.15585/mmwr.mm7137a3
pubmed: 36107786
pmcid: 9484809
Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. The Australian Immunisation Handbook. 2023. https://immunisationhandbook.health.gov.au/home . Accessed 3 Aug 2023.
New Zealand Government Ministry of Health. Immunisation Handbook 2020. Wellington; 2020. https://www.health.govt.nz/our-work/immunisation-handbook-2020 .
Bruce MG, Deeks SL, Zulz T, Bruden D, Navarro C, Lovgren M, et al. International circumpolar surveillance system for invasive pneumococcal disease, 1999–2005. Emerg Infect Dis. 2008;14:25–33.
doi: 10.3201/eid1401.071315
pubmed: 18258073
pmcid: 2600171
Cortese MM, Ketcham J. High incidence rates of invasive pneumococcal disease in the White Mountain Apache population. Arch Intern Med. 1992;152:2277–82.
doi: 10.1001/archinte.1992.00400230087015
pubmed: 1444688
Davidson M, Parkinson AJ, Bulkow LR, Fitzgerald MA, Peters H, Parks DJ. The epidemiology of invasive pneumococcal disease in Alaska, 1986–1990 ethnic differences and opportunities for prevention. J Infect Dis. 1994;170:368–76.
doi: 10.1093/infdis/170.2.368
pubmed: 8035023
Eton V, Schroeter A, Kelly L, Kirlew M, Tsang RSW, Ulanova M. Epidemiology of invasive pneumococcal and Haemophilus influenzae diseases in Northwestern Ontario, Canada, 2010–2015. Int J Infect Dis. 2017;65:27–33.
doi: 10.1016/j.ijid.2017.09.016
pubmed: 28951105
Li Y, Martin I, Tsang R, Squires S, Demczuk W, Desai S. Invasive bacterial diseases in Northern Canada, 2006–2013. Can Commun Dis Rep. 2016;42:74–80.
doi: 10.14745/ccdr.v42i04a01
pubmed: 29770008
pmcid: 5933840
Vaudry W, Talling D. Invasive pneumococcal infection in First Nations children in northern Alberta. Can Commun Dis Rep. 2002;28:165–72.
pubmed: 12402519
Beery QC, Doyle WJ, Bluestone CD, Cantekin EI, Wiet RJ. Eustachian Tube Function in an American Indian Population. Ann Otol Rhinol Laryngol. 1980;89 3_suppl:28–33.
Cuvelier GDE, Rubin TS, Junker A, Sinha R, Rosenberg AM, Wall DA, et al. Clinical presentation, immunologic features, and hematopoietic stem cell transplant outcomes for IKBKB immune deficiency. Clin Immunol. 2019;205:138–47.
doi: 10.1016/j.clim.2018.10.019
pubmed: 30391351
Dalcin D, Sieswerda L, Dubois S, Ulanova M. Epidemiology of invasive pneumococcal disease in Indigenous and non-Indigenous adults in northwestern Ontario, Canada, 2006–2015. BMC Infect Dis. 2018;18:621.
doi: 10.1186/s12879-018-3531-9
pubmed: 30514226
pmcid: 6280531
Lee NR, King A, Vigil D, Mullaney D, Sanderson PR, Ametepee T, et al. Infectious diseases in Indigenous populations in North America: learning from the past to create a more equitable future. Lancet Infect Dis. 2023. https://doi.org/10.1016/S1473-3099(23)00190-1 .
doi: 10.1016/S1473-3099(23)00190-1
pubmed: 37625434
pmcid: 10877583
Levine OS, Farley M, Harrison LH, Lefkowitz L, McGeer A, Schwartz B, et al. Risk factors for invasive pneumococcal disease in children: a population-based case–control study in North America. Pediatrics. 1999;103:e28.
doi: 10.1542/peds.103.3.e28
pubmed: 10049984
Morris K, Morganlander M, Coulehan JL, Gahagen S, Arena VC. Wood-burning stoves and lower respiratory tract infection in American Indian children. Arch Pediatr Adolesc Med. 1990;144:105.
doi: 10.1001/archpedi.1990.02150250117047
Reisman J, Rudolph K, Bruden D, Hurlburt D, Bruce MG, Hennessy T. Risk factors for pneumococcal colonization of the nasopharynx in Alaska native adults and children. J Pediatr Infect Dis Soc. 2014;3:104–11.
doi: 10.1093/jpids/pit069
Wenger JD, Zulz T, Bruden D, Singleton R, Bruce MG, Bulkow L, et al. Invasive pneumococcal disease in Alaskan children: impact of the seven-valent pneumococcal conjugate vaccine and the role of water supply. Pediatr Infect Dis J. 2010;29:251–6.
doi: 10.1097/INF.0b013e3181bdbed5
pubmed: 19952861
Hennessy TW, Ritter T, Holman RC, Bruden DL, Yorita KL, Bulkow L, et al. The relationship between in-home water service and the risk of respiratory tract, skin, and gastrointestinal tract infections among rural Alaska natives. Am J Public Health. 2008;98:2072–8.
doi: 10.2105/AJPH.2007.115618
pubmed: 18382002
pmcid: 2636427
Gessner BG, Ussery XT, Parkinson AJ, Breiman RF. Risk factors for invasive disease caused by streptococcus pneumoniae among Alaska native children younger than two years of age. Pediatr Infect Dis J. 1995;14:123–8.
doi: 10.1097/00006454-199502000-00008
pubmed: 7746694
Scott JR, Millar EV, Lipsitch M, Moulton LH, Weatherholtz R, Perilla MJ, et al. Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in native American communities. J Infect Dis. 2012;205:280–8.
doi: 10.1093/infdis/jir730
pubmed: 22128315
Government of Northwest Territories. Indigenous Peoples – 2021 Census. 2022. https://www.statsnwt.ca/census/2021/Census_IndigenousPeoples.pdf
Government of Alberta. 2021 Census of Canada - Indigenous Peoples. 2023. https://open.alberta.ca/dataset/487a7294-06ac-481e-80b7-5566692a6b11/resource/257af6d4-902c-4761-8fee-3971a4480678/download/tbf-2021-census-of-canada-indigenous-people.pdf
National Collaborating Centre for Indigenous Health. Access to health services as a social determinant of First Nations, Inuit and Métis health. 2019.
Truth and Reconciliation Commission of Canada. Truth and reconciliation commission of Canada: Calls to action. 2015. https://web.archive.org/web/20200506065356/http://trc.ca/assets/pdf/Calls_to_Action_English2.pdf
National Advisory Committee on Immunization. An Advisory Committee Statement: Public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines. Ottawa. 2023. https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/public-health-level-recommendations-use-pneumococcal-vaccines-adults-including-use-15-valent-20-valent-conjugate-vaccines/recommendations-use-pneumococcal-vaccines-adults-15-20-valent-conjugate.pdf